A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants with Advanced Solid Tumors

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516817-19-00

Acronym

MK-3120-002

Enrollment

Registered

2025-05-20

Start date

2025-05-23

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/metastatic solid tumor disease

Brief summary

Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE

Detailed description

Objective Response Rate (ORR), Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS), Area Under the Concentration-Time Curve from 0 to Last Measurable Plasma Concentration (AUC0-last) of MK-3120, Maximum Concentration (Cmax) of MK-3120, Time to Maximum Concentration (Tmax) of MK-3120, Trough Concentration (Ctrough) of MK-3120

Interventions

DRUGMK-3120

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE	—

Secondary

Measure	Time frame
Objective Response Rate (ORR), Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS), Area Under the Concentration-Time Curve from 0 to Last Measurable Plasma Concentration (AUC0-last) of MK-3120, Maximum Concentration (Cmax) of MK-3120, Time to Maximum Concentration (Tmax) of MK-3120, Trough Concentration (Ctrough) of MK-3120	—

Countries

France, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026